MedWatch

Novo Nordisk buys new priority review voucher for FDA

Novo Nordisk has purchased a priority review voucher that ensures the company a quicker review of an application to FDA. The seller is an Australian company.

Foto: Linda Kastrup / Ritzau Scanpix

Once again, Novo Nordisk has gotten the opportunity for a quick review process with the FDA, just like the company did in connection with the ongoing review of its diabetes pill.

The Danish drug group has bought a priority review voucher from Australian biotech firm Medicines Development for Global Health. The Australians received the voucher from FDA last year upon the approval of the drug moxidectin against onchocerciasis, also known as river blindness.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier